US Envoy Demands UK Pay More for Drugs, Not for Your Health
According to the Financial Times, US Ambassador Warren Stephens has issued a stark warning: the UK must significantly increase its drug payments to pharmaceutical companies or face a mass exodus. This 'urgent' intervention suggests that allowing the NHS to negotiate drug prices, a power many sovereign nations enjoy, is simply an unacceptable affront to American corporate interests. Never mind that
the US itself pays some of the highest drug prices globally, subsidizing the research and development that international markets then leverage. One might wonder if Ambassador Stephens (a former private equity executive, one notes) is equally 'urgently raising' concerns about how other nations, like Germany or Canada, seem to manage robust healthcare systems without pharmaceutical companies fleeing
in terror. Or perhaps it's just the UK market that these 'too big to stay' companies find uniquely challenging when faced with anything less than maximal profit extraction. This isn't about innovation; it’s about demanding tribute from a public healthcare system.